Filing Details

Accession Number:
0001127602-19-017457
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-05-06 16:51:03
Reporting Period:
2019-05-02
Accepted Time:
2019-05-06 16:51:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
882796 Biocryst Pharmaceuticals Inc BCRX Biological Products, (No Disgnostic Substances) (2836) 621413174
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1230708 Ii R Thomas Staab 4505 Emperor Blvd.
Suite 200
Durham NC 27703
Senior Vice President And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-05-02 7,750 $5.51 140,426 No 4 M Direct
Common Stock Disposition 2019-05-02 7,750 $7.30 132,676 No 4 S Direct
Common Stock Acquisiton 2019-05-06 9,000 $5.51 141,676 No 4 M Direct
Common Stock Disposition 2019-05-06 9,000 $7.75 132,676 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Emp. Stock Option (Right to Buy) Disposition 2019-05-02 7,750 $0.00 7,750 $5.51
Common Stock Emp. Stock Option (Right to Buy) Disposition 2019-05-06 9,000 $0.00 9,000 $5.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
159,750 2018-02-27 2027-02-27 No 4 M Direct
150,750 2018-02-27 2027-02-27 No 4 M Direct
Footnotes
  1. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019.
  2. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.19 to $7.42. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  3. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.43 to $7.86. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.